BioPharmSignal logoBioPharmSignal

Biotech News

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX)Annexon, Inc.Company update

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted

Open original release

Related news

ANNXAnnexon, Inc.2026-05-27 12:00 EST

Annexon to Participate in Upcoming June Investor Conferences

ANNXAnnexon, Inc.2026-05-06 12:00 EST

Annexon to Present at the Bank of America Securities Health Care Conference 2026

TSHATaysha Gene Therapies2026-06-05 12:01 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IKTInhibikase Therapeutics2026-07-02 20:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-05-05 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-05-01 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XERSXeris Pharmaceuticals2026-04-03 20:15 EST

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BTAIBioXcel2026-05-28 11:00 EST

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

MNOVMediciNova2026-04-27 23:00 EST

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

PRAXPraxis Precision Medicines2026-04-14 11:30 EST

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

View all latest news

Annexon, Inc.

Annexon is a neuroscience company focused on complement biology and autoimmune or neuroinflammatory disease. Its platform is built around modulating immune pathways in the nervous system and beyond.

Recent company news

ANNXAnnexon, Inc.2026-05-27 12:00 EST

Annexon to Participate in Upcoming June Investor Conferences

ANNXAnnexon, Inc.2026-05-07 20:01 EST

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

ANNXAnnexon, Inc.2026-05-06 12:00 EST

Annexon to Present at the Bank of America Securities Health Care Conference 2026

ANNXAnnexon, Inc.2026-04-08 20:05 EST

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

ANNXAnnexon, Inc.2026-03-30 20:01 EST

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Stock data

Close
5.13 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States